Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
The adjusted functional result exceeded the clinically meaningful threshold, but the trial missed its primary imaging endpoint.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alterity Therapeutics (ATHE) presented additional Phase 2 analyses showing ATH434 50 mg slowed functional decline in multiple system atrophy by approximately 52%. The analysis adjusted for baseline cerebrospinal fluid neurofilament light chain, a marker predicting decline. At Week 52, the difference versus placebo was −4.64 points on the 11-item UMSARS Part I daily-function scale (p=0.032), exceeding the 1.5-point minimal clinically important difference.
The analysis included 61 participants and used a statistical model added after the trial to align with imaging analyses. The previously reported clinical analysis showed 46% slowing; the populations and models differ. The primary imaging endpoint was not met, and 75 mg functional results were not statistically significant at Weeks 26 or 52. Adverse event rates were similar to placebo, with no serious adverse events attributed to ATH434. Alterity is preparing to initiate a Phase 3 trial.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointATH434 50 mg slowed functional decline approximately 52% versus placebo at Week 52 after baseline biomarker adjustment.
- Minor point−4.64-point difference versus placebo exceeded the 1.5-point clinically important threshold at Week 52 (p=0.032).
- Minor pointBaseline CSF NfL predicted Week 52 decline: approximately 0.9 additional worsening points per 1,000 pg/mL increase (p=0.033).
- Minor pointPutamen and globus pallidus iron changes were numerically lower with ATH434 versus placebo in adjusted imaging analyses.
- Minor pointAdditional efficacy assessments showed trends toward improved motor performance, swallowing and orthostatic hypotension symptoms.
4 minor points
- Minor pointWearable sensor data indicated increased activity outside the clinic with ATH434.
- Minor pointBrain volume showed preservation trends in the Phase 2 trial.
- Minor pointAdverse event rates were similar to placebo, with no serious adverse events attributed to ATH434.
- Minor pointPhase 3 pivotal trial preparation is underway at Alterity.
Negative
- Major pointPrimary imaging endpoint of change in substantia nigra iron at Week 52 was not met.
- Moderate pointATH434 75 mg functional results were not statistically significant at Week 26 (p=0.072) or Week 52 (p=0.179).
- Moderate pointUpdated functional analysis used a post hoc statistical model and a modified population of 61 participants.
- Minor pointMRI measurement limitation prevents measuring iron stored or buffered within cells; the redistribution explanation remains a hypothesis.
News Explained
In the adjusted MRI analysis, dentate-nucleus iron signal at Week 52 was higher versus placebo with 50 mg (+0.016 ppm, p=0.021); the poster hypothesizes this may reflect iron redistribution, while noting MRI cannot measure iron stored or buffered inside cells.
Key Figures
- Functional decline slowing
- Approximately 52%
- ATH434 50 mg versus placebo at Week 52, after baseline CSF NfL adjustment
- UMSARS Part I difference
- −4.64 points (p=0.032)
- ATH434 50 mg versus placebo in change from baseline at Week 52
- Analysis population
- 61 participants
- Modified Intent-to-treat population used for the analysis
- CSF NfL association
- 0.9 additional points per 1,000 pg/mL (p=0.033)
- Greater UMSARS I worsening at Week 52 with higher baseline CSF NfL
- 75 mg dose difference
- −2.81 points (Week 26 p=0.072; Week 52 p=0.179)
- UMSARS Part I change from baseline versus placebo
- Primary imaging endpoint
- Not met
- Change in substantia nigra iron at Week 52
- Dentate nucleus iron signal
- +0.016 ppm (p=0.021)
- ATH434 50 mg relative to placebo at Week 52
- Minimal clinically important difference
- 1.5 points
- UMSARS Part I comparison cited for the Week 52 treatment effect
Previous Clinical trial Reports
-
Earlier ATH434 Phase 2 analyses reported 50 mg benefits on modified UMSARS Part I and MuSyCA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
csf n f l medical
mmrm technical
mcid medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATH434 50 mg significantly slowed functional decline in MSA by approximately
Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3
MELBOURNE, Australia and SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that additional analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) were presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Seoul, Korea. The poster brings together clinical, biomarker, and imaging results from the trial after adjusting for baseline disease severity, measured by cerebrospinal fluid neurofilament light chain (CSF NfL).
“These additional analyses strengthen our confidence in ATH434 as a potential disease-modifying therapy for MSA. When we account for differences in baseline disease severity using CSF NfL, ATH434 50 mg significantly slowed functional decline by more than
“I continue to be impressed by the strength of the efficacy signal in our Phase 2 study in the context of other treatments that are in development for MSA. By incorporating the learnings regarding NfL into our Phase 3 confirmatory trial, we continue to build on our de-risking strategy that has been so successful in Phase 2,” concluded Dr. Stamler.
The poster, entitled, “ATH434 in Multiple System Atrophy: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study with CSF Neurofilament Light Chain as a Disease Severity Covariate,” analyzed baseline CSF NfL, an established prognostic biomarker of clinical decline in MSA, as a covariate to account for variability in baseline disease severity.
The analysis demonstrated that CSF NfL, a prespecified covariate in the Phase 2 trial, predicts functional decline in individuals with MSA. Higher baseline CSF NfL predicted greater decline at Week 52: each 1,000 pg/mL increase was associated with approximately 0.9 additional points of worsening on UMSARS I1, an effect that was significant (p=0.033). This supports using CSF NfL as a covariate in future MSA trials since adjusting for a known predictor of decline can produce a more precise measurement of treatment effect.
ATH434 50 mg significantly slowed functional decline on the 11-item UMSARS Part I
The analysis utilized a mixed model for repeated measures (MMRM)2 applied to align with the imaging analyses conducted on the Modified Intent-to-treat (mITT) population (N=61)3. After adjustment for baseline CSF NFL, ATH434 50 mg significantly slowed functional decline on the 11-item UMSARS Part I4 at Week 52 with a −4.64-point difference versus placebo in change from baseline (p=0.032), roughly 3-fold more improvement compared to the 1.5-point minimal clinically important difference (MCID). This represents an approximate
Advanced brain iron MRI imaging is consistent with the ATH434 mechanism of action as an iron-chaperone
The poster also reported brain iron measured by quantitative susceptibility mapping (QSM) MRI analyzed with the same CSF NfL-adjusted model. ATH434 is designed as an iron chaperone and is intended to redistribute reactive (labile) iron that is driving MSA pathology. MRI can detect iron leaving cells but cannot measure iron that has been stored or buffered within cells. Although the trial’s primary endpoint of change in substantia nigra iron at Week 52 was not met, change from baseline in iron was numerically lower in the putamen and globus pallidus with ATH434 vs placebo. In the dentate nucleus, iron signal increased relative to placebo at Week 52 (50 mg: +0.016 ppm, p=0.021), which is hypothesized to reflect redistribution of mobilized iron through the brain’s glymphatic system. The poster noted that regional differences may reflect region-specific iron handling because an MRI captures iron efflux but not the potential storage or buffering effects of ATH434.
The presentation is available on the Alterity Therapeutics website here.
About ATH434-201 Phase 2 Clinical Trial
The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy, safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or 75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 50 mg produced clinically and statistically significant slowing of decline on the 11-item Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, a functional rating scale that assesses disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the positive UMSARS Part I findings including trends in improved motor performance on the Clinical Global Impression of Severity Scale, the Swallowing Disturbance Questionnaire and the Orthostatic Hypotension Symptom Assessment. Wearable sensor data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect and target engagement relative to placebo. Both dose levels reduced iron accumulation in MSA affected brain regions with trends in preservation of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091.
About Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects up to 50,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.4
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
References:
1 UMSARS: 11-item Unified Multiple System Atrophy Rating Scale Part I (excludes sexual function)
2 Mixed Models for Repeated Measures (MMRM) analysis using all visits without imputation (treatment, visit, treatment-by-visit interaction, sex; covariates age, baseline score, baseline CSF NfL), added post hoc to align with the imaging analyses; the prespecified analysis was a Week 52 Analysis of Covariance (ANCOVA).
3 Modified Intent-to-treat (mITT) population (N=61): randomized and dosed, CSF α-synuclein seed amplification assay positive, with ≥1 postbaseline QSM assessment.
4 Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alterity's new ATH434 Phase 2 analysis show for functional decline in MSA?
ATH434 50 mg slowed functional decline by approximately 52% versus placebo at Week 52 after adjustment for baseline cerebrospinal fluid neurofilament light chain. The difference in change from baseline was −4.64 points on the 11-item UMSARS Part I scale (p=0.032), compared with a 1.5-point minimal clinically important difference.
Did Alterity's ATH434 Phase 2 trial meet its primary imaging endpoint?
The primary endpoint was not met: change in substantia nigra iron at Week 52. Adjusted imaging analyses showed numerically lower changes in iron in the putamen and globus pallidus with ATH434 versus placebo.
Who was included in Alterity's updated ATH434 Phase 2 analysis?
The 61-participant modified intent-to-treat population included participants who were randomized and dosed, tested positive on a cerebrospinal fluid alpha-synuclein seed amplification assay, and had at least one brain iron MRI assessment after baseline. The trial enrolled 77 adults assigned to ATH434 50 mg or 75 mg twice daily, or matching placebo.
What did Alterity's ATH434 analysis find about iron in the dentate nucleus?
The 50 mg group had a +0.016 ppm iron-signal increase relative to placebo in the dentate nucleus at Week 52 (p=0.021). Alterity hypothesizes that this reflects redistribution of mobilized iron through the brain's glymphatic system, a fluid-clearance pathway; it is not a confirmed explanation.